Wed, Jul 30, 2014, 5:06 AM EDT - U.S. Markets open in 4 hrs 24 mins

Recent

% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

  • believe220000 believe220000 Jul 1, 2013 2:32 PM Flag

    Results For Insmed's Arikace Disappoints; Shares Fall 19% 07/01 02:23 PM

    02:23 PM EDT, 07/01/2013 (MidnightTrader) -- Insmed (INSM:$9.68,00$-2.28,00-19.06%) shares down 19% at $9.66 as phase 3 study results for INSM's drug Arikace disappoint. Arikace, which treats certain lung infections in patients with cystic fibrosis, met the study's primary endpoint, but investors were hoping for the drug to show superiority over other treatments, specifically Novartis's (NVS) Tobi which showed more favorable results.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 02:23 PM EDT, 07/01/2013 (MidnightTrader) -- Insmed (INSM:$9.68,00$-2.28,00-19.06%) shares down 19% at $9.66 as phase 3 study results for INSM's drug Arikace disappoint. Arikace, which treats certain lung infections in patients with cystic fibrosis, met the study's primary endpoint, but investors were hoping for the drug to show superiority over other treatments, specifically Novartis's (NVS) Tobi which showed more favorable results.

    • 02:23 PM EDT, 07/01/2013 (MidnightTrader) -- Insmed (INSM:$9.68,00$-2.28,00-19.06%) shares down 19% at $9.66 as phase 3 study results for INSM's drug Arikace disappoint. Arikace, which treats certain lung infections in patients with cystic fibrosis, met the study's primary endpoint, but investors were hoping for the drug to show superiority over other treatments, specifically Novartis's (NVS) Tobi which showed more favorable results

    • REALITY=investors were hoping for the drug to show superiority over other treatments, specifically Novartis's (NVS) Tobi which showed more favorable results.

      02:23 PM EDT, 07/01/2013 (MidnightTrader) -- Insmed (INSM:$9.68,00$-2.28,00-19.06%) shares down 19% at $9.66 as phase 3 study results for INSM's drug Arikace disappoint. Arikace, which treats certain lung infections in patients with cystic fibrosis, met the study's primary endpoint, but investors were hoping for the drug to show superiority over other treatments, specifically Novartis's (NVS) Tobi which showed more favorable results. Less

 
INSM
17.50+0.40(+2.34%)Jul 29 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.